Merck KGaA sees higher profits on cost cutting; Daiichi chair steps down amid Ranbaxy sale;

@FiercePharma: GlaxoSmithKline exec blindsided by Chinese bribery charges: Reuters. Report | Follow @FiercePharma

@TracyStaton: Words, words, and overheated words fly as U.K. officials keep grilling Pfizer. ICYMI yesterday | Follow @TracyStaton

@EricPFierce: Canada orders Biolyse to halt production of injectable drug paclitaxel at a plant in Ontario.More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FiercePharmaMarketing: Report | Follow @CarlyHFierce

> Germany-based Merck KGaA said cost cuts help offset negative currency effects in its first-quarter results, which included a slight rise in earnings to 807 million euros, or about $1.11 billion. Report

> The chairman of Japanese drugmaker Daiichi Sankyo, Takashi Shoda, is stepping down as the company offloads the troubled Indian generics company Ranbaxy Laboratories, whose acquisition he engineered. Report

> India's Wockhardt recalled 109,000 bottles of its generic version of the heart pill Toprol XL in the U.S., after the pills failed dissolution tests. Report

> Reckitt Benckiser signed on to develop and sell XenoPort's drug to treat alcoholism, with a $20 million up front payment and up to $120 million in milestones. Report

> Slovenia's Krka posted a 17% drop in first-quarter profits to €42.5 million, blaming the results on negative currency effects that took a €14 million bite out of earnings. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: J&J's new incubator opens its arms to med tech startups. Article | Follow @FierceMedDev

@VarunSaxena2: Interesting FDA meeting summary. "The following questions were discussed:" [copy Qs from preview] [paste]. More | Follow @VarunSaxena2

@MichaelGFierce: Boston College team makes zinc nano-cages for 'smart' cancer drug delivery. ICYMI from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Stabilizing spoon counteracts tremors, helps Parkinson's patients eat. More from NPR | Follow @EmilyWFierce

> Boston Scientific to buy Bayer's device unit for $415 million. More

> Refuse to Accept policy not leading to faster approvals. Story

> Purdue engineering students develop device to test pacemaker lead attachment. Article

Biotech News

@FierceBiotech: AstraZeneca: Coming up from behind--fast--with top cancer programs. Story | Follow @FierceBiotech

@JohnCFierce: ZS Pharma looks to $86M IPO to fund PhIII hyperkalemia studies. News | Follow @JohnCFierce

@DamianFierce: NY Times "the only newsroom in the country that is actually better than it was a generation ago," reports NY TimesMore | Follow @DamianFierce

@EmilyMFierce: Investigational treatment may provide relief for asthma. More from FierceBiotechResearch | Follow @EmilyMFierce

> Novartis-backed Sorbent grabs first tranche in $15M heart therapy round. More

> Bristol-Myers Squibb: It's all about the 'breakthrough' drug nivolumab now. Report

> Bluebird bio buoyed by news of looming trial data. Item

Pharma Manufacturing News

> The man behind Daiichi Sankyo buyout of Ranbaxy gives up chairman's role. More

> Daiichi Sankyo turns over domestic logistics to Yasuda Warehouse. Report

> Hospira says it can prevent shortage after Canada closes Biolyse plant. Article

> Wockhardt recalling 110,000 bottles of generic Toprol XL. More

> Couple who ran wholesaling scam plead guilty. News

Vaccines News

> Mayo Clinic: Massive dose of measles vax killed cancer. Item

> Computer model can boost child vaccination rates while cutting costs. More

> MERS an 'emerging market opportunity,' Novavax CFO says. Report

> People most in need of Merck's shingles jab often not vaccinated. Story

> Sanofi steps up meningitis marketing amid lagging Menactra sales. Article

And Finally... Honey bees crucial to crop pollination are still dying off at a significant rate, a new report states. Report

Suggested Articles

Novartis is rolling out head-to-head data for its MS drug in advance of an expected FDA approval next month, but competition will still be tough.

The FDA knocked Altaire Pharmaceuticals for falsified data and harebrained contraptions at its New York plant in a scathing warning letter.

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.